Boardrooms to Factory Floors: Sectors Powering India’s Corporate Travel Surge

IT, manufacturing & pharma are the three sectors fueling India’s corporate travel boom

By Vinod Kumar Sah, CTO, CoTrav

Every quarter, we review our booking data and the story it tells has stopped surprising me. From the Bengaluru techie flying into Hyderabad for a product sprint, to the pharma regulatory manager shuttling between Ahmedabad and Vizag, to the plant engineer commuting between Pune and a new factory floor in Dharwad India’s corporate traveler is moving faster, farther, and more frequently than ever. And three sectors are driving almost all of it.

India’s corporate travel market, valued at $11 billion and projected to nearly double to $20.8 billion by FY2030 (Deloitte India), is not growing uniformly. It is being pulled forward by a specific trio: the information technology, manufacturing, and pharmaceuticals sectors that together account for 86% of corporate travel spend among India’s top 100 listed firms. This isn’t a post-pandemic rebound. It’s a structural shift. And it demands an entirely new playbook.

IT: The GCC Effect is Rewriting the Map

India crossed 1,800 Global Capability Centers by late 2025, with projections pointing to 2,400 by 2030. These are no longer back-office support units they own product roadmaps, run AI labs, and carry P&L responsibility. Each new GCC is a new engine of internal travel: teams flying to parent-company headquarters for governance reviews, cybersecurity leads travelling for inter-GCC knowledge exchanges, product heads boarding flights for board-level presentations.

The tier-2 acceleration is equally significant. With Bengaluru office rents rising roughly 20% in early 2025, companies are seeding GCC operations in Ahmedabad, Coimbatore, Bhubaneswar, and Lucknow cities now generating corporate travel demand that simply didn’t exist three years ago.

Manufacturing: PLI Has Put India’s Factories on the Map and Its Managers on the Move

The Production Linked Incentive scheme is arguably the most consequential industrial policy India has executed in decades. By March 2025, realized investments crossed ₹1.76 lakh crore, catalyzing expansion across electronics, automotive, textiles, and chemicals particularly in tier-2 and tier-3 corridors like Sanand, Hosur, and Kalinganagar.

Manufacturing doesn’t run on Zoom calls. Supplier audits, quality inspections, and facility ramp-ups demand physical presence. India’s electronics ambitions add a cross-border dimension: semiconductor projects greenlit in Odisha and Andhra Pradesh, Apple’s supply chain deepening in Tamil Nadu, engineers flying to Taiwan for supplier alignment. For India’s manufacturing professionals, this is simply the job now.

Pharma: The Pharmacy of the World Travels Extensively to Stay That Way

With over 650 USFDA-approved facilities more than any country outside the US India’s pharma sector is extraordinarily travel-intensive. Every regulatory inspection, pre-approval visit, and corrective action plan involves international movement. Regulatory affairs professionals rank among the most frequent flyers in any large pharma firm, alongside clinical trial coordinators and business development teams building CDMO partnerships across Europe and Southeast Asia.

The ₹15,000 crore PLI scheme for pharmaceuticals is meanwhile pushing expansion into Hyderabad’s pharma corridor, Baddi, and Vapi. With domestic pharma sales projected to nearly double to $50 billion by 2030 tier-2 and tier-3 cities driving over 40% of that growth every new distribution footprint translates directly into field force travel.

What This Means for Travel Management

The implications are practical and urgent.

The geography of corporate India has permanently expanded. A program optimized only for the Bengaluru–Mumbai–Delhi triangle is already obsolete. Tier-2 connectivity its constraints and its innovations, including 60+ new UDAN routes since 2024 must be built into every managed travel program from the ground up.

Traveler profiles are diversifying. The GCC engineer wants a self-serve app with instant approvals. The pharma regulatory director wants a concierge who knows that Hyderabad to Boston has exactly one routing that makes a morning FDA meeting. One-size-fits-all is a liability.

And leisure is no longer a fringe benefit it’s a retention lever. With 37% of Indian corporate travelers extending trips for leisure, a rigid policy that blocks this is simply a culture tax.

India’s corporate travel boom isn’t a story about seat counts and room nights. It’s a story about an economy in motion building, scaling, supplying. The three sectors driving it aren’t slowing down. Neither should the systems designed to move the people who power them.